Ildiko Lingvay1, Cyrus V Desouza2, Katarina S Lalic3, Ludger Rose4, Thomas Hansen5, Jeppe Zacho5, Thomas R Pieber6. 1. University of Texas Southwestern Medical Center at Dallas, Dallas, TX. 2. University of Nebraska Medical Center, Omaha, NE. 3. Faculty of Medicine, University of Belgrade, and Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia. 4. Institute for Diabetes Research in Münster, Münster, Germany. 5. Novo Nordisk A/S, Søborg, Denmark. 6. Medical University of Graz, Graz, Austria thomas.pieber@medunigraz.at.
Abstract
OBJECTIVE: To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA1c 7.0-10.0% (53-86 mmol/mol) and treated withdiet and exercise with or without metformin. Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group). Primary end point was change in HbA1c from baseline to week 26. RESULTS: In total, 705 randomized patients were exposed to trial products. At week 26, a dose-dependent change in HbA1c was observed with semaglutide from -1.1% (0.05 mg) to -1.9% (0.3 mg) and with liraglutide from -0.5% (0.3 mg) to -1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose). Change with pooled placebo was -0.02% (P < 0.0001 vs. semaglutide). Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8-54.0% and 21.9-41.5% of patients, respectively. CONCLUSIONS: Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA1c compared with liraglutide or placebo but with a higher frequency of GI AEs.
RCT Entities:
OBJECTIVE: To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin. Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group). Primary end point was change in HbA1c from baseline to week 26. RESULTS: In total, 705 randomized patients were exposed to trial products. At week 26, a dose-dependent change in HbA1c was observed with semaglutide from -1.1% (0.05 mg) to -1.9% (0.3 mg) and with liraglutide from -0.5% (0.3 mg) to -1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose). Change with pooled placebo was -0.02% (P < 0.0001 vs. semaglutide). Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8-54.0% and 21.9-41.5% of patients, respectively. CONCLUSIONS: Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA1c compared with liraglutide or placebo but with a higher frequency of GI AEs.
Authors: Claudia G Liberini; Rinzin Lhamo; Misgana Ghidewon; Tyler Ling; Nina Juntereal; Jack Chen; Anh Cao; Lauren M Stein; Matthew R Hayes Journal: Diabetes Obes Metab Date: 2018-12-21 Impact factor: 6.577
Authors: Sushrima Gan; Adem Y Dawed; Louise A Donnelly; Anand T N Nair; Colin N A Palmer; Viswanathan Mohan; Ewan R Pearson Journal: Diabetes Care Date: 2020-08 Impact factor: 19.112
Authors: Robert F Kushner; Salvatore Calanna; Melanie Davies; Dror Dicker; W Timothy Garvey; Bryan Goldman; Ildiko Lingvay; Mette Thomsen; Thomas A Wadden; Sean Wharton; John P H Wilding; Domenica Rubino Journal: Obesity (Silver Spring) Date: 2020-06 Impact factor: 5.002
Authors: Christina Antza; Krishnarajah Nirantharakumar; Ioannis Doundoulakis; Abd A Tahrani; Konstantinos A Toulis Journal: Drug Des Devel Ther Date: 2019-08-22 Impact factor: 4.162
Authors: Louis S Matza; Kristina S Boye; Katie D Stewart; Karin S Coyne; Paula K Wullenweber; Katelyn N Cutts; Jessica B Jordan; Qianqian Wang; Maria Yu; Brooke M Currie; Karen G Malley; K Jack Ishak; Ryan T Hietpas; Luis-Emilio García-Pérez Journal: Diabetes Obes Metab Date: 2019-12-19 Impact factor: 6.577
Authors: Sanaz Kamalinia; Robert G Josse; Patrick J Donio; Lindsay Leduc; Baiju R Shah; Sheldon W Tobe Journal: Endocrinol Diabetes Metab Date: 2019-11-13